Febuxostat- a new treatment for hyperuricaemia in gout - a review article

Anjana Pandey, Mridul Chaturvedi, Himanshu Prakash, Daulat, Meena

2022, Vol: 12, Issue: 1

12/1Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

Authorship Declaration

« Previous Article

Review Article

Natl J Physiol Pharm Pharmacol. 2012; 2(1): 23-28

Febuxostat- a new treatment for hyperuricaemia in gout - a review article

Anjana Pandey, Mridul Chaturvedi, Himanshu Prakash, Daulat, Meena.

Cited by (1)

Abstract
Febuxostat, a novel, orally administered, potent, nonâ€“purine analogue, xanthine oxidase inhibitor in the management of hyperuricemia in patients with gout & chronic tophaceous gout. It has minimal effects on other enzymes involved in purine and pyrimidine metabolism, and is metabolized mainly by glucuronide formation and oxidation in the liver. In a study of subjects with renal impairment, the serum urateâ€“lowering effect of febuxostat was unaltered. Febuxostat, at a daily dose of 80 mg or 120 mg, was more effective than allopurinol at the commonly used fixed daily dose of 300 mg in lowering serum urate.

Key words: Febuxostat, xanthine oxidase inhibitor, chronic tophaceous gout, renal impairment

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Anjana Pandey Articles by Mridul Chaturvedi Articles by Himanshu Prakash Articles by Daulat Articles by Meena
	on Google
	on Google Scholar

This Article Cited By the following articles

Trends of articles published in National Journal of Physiology, Pharmacy and Pharmacology NJPPP National Journal of Physiology, Pharmacy and Pharmacology 2013; 3(2): 102.	1

How to Cite this Article

Pubmed Style

Anjana Pandey, Mridul Chaturvedi, Himanshu Prakash, Daulat, Meena. Febuxostat- a new treatment for hyperuricaemia in gout - a review article. Natl J Physiol Pharm Pharmacol. 2012; 2(1): 23-28.

Web Style

Anjana Pandey, Mridul Chaturvedi, Himanshu Prakash, Daulat, Meena. Febuxostat- a new treatment for hyperuricaemia in gout - a review article. http://www.njppp.com/?mno=9970 [Access: January 02, 2022].

AMA (American Medical Association) Style

Anjana Pandey, Mridul Chaturvedi, Himanshu Prakash, Daulat, Meena. Febuxostat- a new treatment for hyperuricaemia in gout - a review article. Natl J Physiol Pharm Pharmacol. 2012; 2(1): 23-28.

Vancouver/ICMJE Style

Anjana Pandey, Mridul Chaturvedi, Himanshu Prakash, Daulat, Meena. Febuxostat- a new treatment for hyperuricaemia in gout - a review article. Natl J Physiol Pharm Pharmacol. (2012), [cited January 02, 2022]; 2(1): 23-28.

Harvard Style

Anjana Pandey, Mridul Chaturvedi, Himanshu Prakash, Daulat, Meena (2012) Febuxostat- a new treatment for hyperuricaemia in gout - a review article. Natl J Physiol Pharm Pharmacol, 2 (1), 23-28.

Turabian Style

Anjana Pandey, Mridul Chaturvedi, Himanshu Prakash, Daulat, Meena. 2012. Febuxostat- a new treatment for hyperuricaemia in gout - a review article. National Journal of Physiology, Pharmacy and Pharmacology, 2 (1), 23-28.

Chicago Style

Anjana Pandey, Mridul Chaturvedi, Himanshu Prakash, Daulat, Meena. "Febuxostat- a new treatment for hyperuricaemia in gout - a review article." National Journal of Physiology, Pharmacy and Pharmacology 2 (2012), 23-28.

MLA (The Modern Language Association) Style

APA (American Psychological Association) Style

Anjana Pandey, Mridul Chaturvedi, Himanshu Prakash, Daulat, Meena (2012) Febuxostat- a new treatment for hyperuricaemia in gout - a review article. National Journal of Physiology, Pharmacy and Pharmacology, 2 (1), 23-28.



Copyright © 2022 National Journal of Physiology, Pharmacy and Pharmacology All Rights Reserved. Subject to change without notice from or liability to National Journal of Physiology, Pharmacy and Pharmacology. For best results, please use Internet Explorer or Google Chrome	Contact Information Publisher publishernjppp@gmail.com Editorial query editornjppp1@gmail.com MOB - 8780040272

Contact Information

How to cite this article